# Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
Canonical URL: https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-presents-new-positive-clinical-cardiometabolic-data-at-the-94th-european-atherosclerosis-society-eas-congress
Ticker: ARWR
Company: Arrowhead Pharmaceuticals
Source: Arrowhead Pharmaceuticals
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.arrowheadpharma.com
## Summary

- New data support potential use of plozasiran without dose adjustment in patients with moderate-to-severe renal or moderate hepatic impairment - Case report suggests that preconception exposure to plozasiran may be associated with sustained lowering of fasting triglyceride levels throughout the

## Article Body
- New data support potential use of plozasiran without dose adjustment in patients with moderate-to-severe renal or moderate hepatic impairment - Case report suggests that preconception exposure to plozasiran may be associated with sustained lowering of fasting triglyceride levels throughout the
## Recent Company News
- 2026-06-25 13:46 EST — [Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-receives-marketing-authorization-in-the-european-union-for-redemplor-plozasiran-to-reduce-triglycerides-in-adults-with-familial-chylomicronemia-syndrome-fcs) — Source: Arrowhead Pharmaceuticals
- 2026-06-25 13:46 EST — [Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-to-host-a-webinar-on-its-cardiometabolic-pipeline-as-part-i-of-the-2026-summer-series-of-randd-webinars) — Source: Arrowhead Pharmaceuticals
- 2026-06-25 13:46 EST — [Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-to-participate-in-upcoming-june-2026-events) — Source: Arrowhead Pharmaceuticals
- 2026-06-25 13:46 EST — [Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-presents-new-clinical-data-on-rnai-based-obesity-and-mash-candidate-aro-inhbe-at-easl-2026) — Source: Arrowhead Pharmaceuticals
- 2026-06-25 13:46 EST — [Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-presents-new-positive-clinical-cardiometabolic-data-at-the-94th-european-atherosclerosis-society-eas-congress) — Source: Arrowhead Pharmaceuticals
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)